Hypnion, Inc.

Hypnion is a privately held drug discovery company developing novel therapeutics for the treatment of central nervous system (CNS) disorders. We are currently focused on the treatment of sleep and wake-alertness disorders and circadian rhythm abnormalities. Founded in 2000, by five prominent sleep disorders researchers, the company is headquartered in Lexington, Massachusetts, and employees over 35 full-time employees and 15 consultants, including many of the world's most renowned sleep disorder and circadian rhythm experts. Combining the talents of a world-class research team, and the predictive modeling capabilities of our core drug discovery technology platform SCORE-2004 , we are able to dramatically shorten the drug discovery process. Hypnion's lead program, a novel sedative-hypnotic, developed utilizing SCORE-2004, went from initial lead to the clinic in just 12 months. Phase I clinical trial data shows this compound to have a significantly superior efficacy and side-effect...